Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ataciguat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HMR1766

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rancho Santa Fe Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 17, 2021

            Details:

            This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TOTUM-070

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 15, 2021

            Details:

            The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TOTUM-070

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 27, 2020

            Details:

            The clinical study HEART on TOTUM-070, a Phase II randomized placebo-controlled and double blind study, has just been initiated in accordance with the road map, the study protocol having been submitted to the French health authorities.